Live
10x Genomics BlogUS-based 10x Genomics establishes first dedicated R&D lab in Singapore - BioSpectrum AsiaClinical OMICsProtein Biomarkers in Practice: Strategies to Reduce Drug Development RiskClinical OMICsMayo Clinic’s REDMOD AI Doubles Early Detection Sensitivity in Pancreatic CancerFierceBiotechIpsen scuttles liver disease candidates from $952M Albireo acquisitionAmgenBiopharma Manufacturing Expands in the U.S.: Amgen, Lilly Double Down on Capacity and Next-Gen Production - BioPharm InternationalEndpoints NewsAmgen, AbbVie say IRA negotiations impacted Q1 salesClinical OMICsAt-Home Blood Test Screens for Early DementiaClinical OMICsGlioblastoma: Testosterone Supplements Linked to 38% Lower Risk of DeathEndpoints NewsLilly plans new $4.5B manufacturing investment in IndianaEndpoints NewsBeOne culls five cancer programs and an autoimmune Phase 2Endpoints NewsLonza looks to ride ADC wave with upcoming factory, workforce expansionFierceBiotechBipartisan PRIMATE Act aims to ban monkey imports to US
Illumina Mar 22, 2026

Swiss Life Asset Management Ltd Purchases 67,772 Shares of Illumina, Inc. $ILMN - MarketBeat

Swiss Life Asset Management Ltd Purchases 67,772 Shares of Illumina, Inc. $ILMN - MarketBeat

Original
Body unavailable. Use the original source.